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Edited by Robert BaroukiAbstract Regulation of Thyrotropin Releasing Hormone
(TRH) transcription in the hypothalamus represents the central
control point of thyroid function. To examine the expression of
potential TRH regulatory components, we simultaneously am-
pliﬁed, by semi-quantitative multiplex PCR system, nine key
genes from £100 ng total RNA from two brain areas (hypothal-
amus and cortex) under diﬀerent thyroid states. Expression of
TR1 and TR2 isoforms, key elements in TRH regulation, was
modiﬁed by thyroid status in the hypothalamus but not in the
cortex. Similarly, hypothyroidism increased speciﬁcally hypo-
thalamic levels of three co-modulator genes. This study provides
the ﬁrst demonstration of tissue speciﬁc co-regulation of a set of
genes by thyroid status within a deﬁned brain area.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Diﬀerential gene activity largely accounts for the regulation
of cell diﬀerentiation underlying development and for tissue
speciﬁc contributions to homeostasis. Many physiological
regulations require strict temporal and spatial regulation of
gene activity. One paradigm for diﬀerential gene regulation in
a deﬁned neuronal context is that of hypothalamic speciﬁc
transcriptional regulation of Thyrotropin Releasing Hormone
(TRH), speciﬁcally regulated by thyroid hormones in the pa-
raventricular nuclei (PVN) of the hypothalamus [1,2]. This
regulation represents the central control point of thyroid
function. Tri-iodothyronine (T3)-dependent repression of TRH
transcription occurs through thyroid receptors (TR), members
of the nuclear receptor superfamily.
As for other nuclear receptors, TR action is modulated by
interaction with co-regulator proteins (for review, see [3,4]).
Little is known about TR and co-modulator regulation in the
hypothalamus and whether tissue speciﬁc regulation of the
genes encoding proteins potentially involved in TRH regula-
tion occurs.* Corresponding author. Fax: +33-1-40-79-36-07.
E-mail address: demeneix@mnhn.fr (B.A. Demeneix).
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doi:10.1016/j.febslet.2004.05.076To address these questions, we set up a semi-quantitative
multiplex PCR system to analyze, among the genes potentially
involved in T3-dependent TRH gene regulation, which ones
were speciﬁcally regulated by thyroid status in the PVN. To
verify the PVN-speciﬁc nature of the regulation, we analyzed
the expression of the same genes in another brain region, i.e.,
the motor and cingulate cortex, where TRH is not expressed.
The results bolster the hypothesis that TRb receptors and both
co-repressors and co-activators can act synergistically to play
modulatory roles in TRH regulation and that their regulation
by thyroid status is PVN speciﬁc.2. Materials and methods
2.1. Animal care and treatment
Animal studies were approved by the Direction des Services Veter-
inaires de Paris and conducted in accordance with the principles and
procedures of the NIH Guidelines for Care and Use of Experimental
Animals.
Hypo- or hyperthyroidism (T3 levels: 16.42 3.51 and 981 111 ng/
dl, respectively, vs. 69.30 1.96 ng/dl for euthyroidism) was induced in
male OF1 six weeks old mice (Janvier, Le Genest St Isle, France) as
described by Dupre et al. [5] for 13 days.
2.2. Tissue isolation
Animals were decapitated after light anesthesia with diethyl ether.
To respect circadian rhythms, animals were always sampled between
10 a.m. and 12 a.m. Plasma samples were taken for veriﬁcation of
thyroid status (as in Dupre et al. [5]). Brains were removed, and the
PVN and the area corresponding to the motor and cingulated cortex
were micro-dissected and kept in RNAlater (Ambion Inc., Austin, TX,
USA).
2.3. RNA extraction and cDNA synthesis
PVN from three mice were pooled and total RNAs from PVN or
cortex were extracted using RNAble (Eurobio, Les Ulis, France) fol-
lowing the manufacturer’s protocol. From 100 ng to 1 lg of total RNA
were reverse-transcribed using Superscript II RNase H reverse-
transcriptase (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Control reactions were done without reverse-
transcriptase. Final cDNA reaction products were diluted with H2O to
concentrations corresponding to 20 ng of starting RNA (20 ng RNA
equivalents) per microliter and stored at )80 C.
2.4. Primers
Multiplex primer design was optimized according to Henegariu et al.
[6] and Zangerberg et al. [7], using Oligo 4.0 S software (National
Biosciences Inc., Plymouth, USA). Brieﬂy, primers fulﬁlled the fol-
lowing conditions: 20 to 26 mer, with TT or CC at the 30 terminus to
avoid primer dimerization, with a GC content between 40% and 60%
and an annealing temperature of 60 1 C. The ampliﬁed sequences
were between 102 and 357 bp long and were chosen in regions of leastation of European Biochemical Societies.
Table 1
Sequence of oligonucleotide primers used in the semi-quantitative multiplex RT-PCR experiments: oligonucleotide positions are indicated as
subscript
Gene
name
Size (bp) 50 Oligonucleotide (50–30) 30 Oligonucleotide (50–30) GenBankTM Primer
(nM)
TRa1 168 1251CAG AGG GTG GGA GCT GGT CCT GTC CAA GGG CTG GAG GGT X51983 800
TRa2 102 1215GCA TGT TGT TCA GGG TCC GCA GGT GGG CTC TTC GGG CTC TGG TGC T X07751.1 50
TRb1 155 41GAA TGC CAG TAC AGA AGA TGA CCC GTG CAG GCA GGC TTC AGA CAT T S62756.1 50
TRb2 143 97AGT CCG GCT CTC AGT GGT CGT GCC ATG TCC AAG TCA GAG TCC NM-009380.1 250
TRH 253 14GGC TGA TGA TGG CTC TGG CTT T ACG TCT TCC TCC TTC TCC TCC CTT T NM-009426 50
NcoR 321 3506TTT CAT CGT TGC GGG GCT CTA TT TCC TTC CAC TGC CTC ATA GCT TCT TT NM-011308 100
SMRT 284 359CAT CAC CCC TGC TGG CCA CT CCA GGC TTC GGT GCT TTG ATT AP113001 200
CBP 357 1270ATG ACT GTC CTG TTT GCC TCC CTT T TTG GTG GCT GTT GAT CTG TTG TTA TT S66385 75
SRC1 233 2102GCA GCC CCT CAG ACA TCA CCA CTT CTT TAC GTC ATC CAG GCA CAG GTT U64828 100
Fig. 1. Semi-quantitative multiplex PCR optimization and application
to RNA from PVN and cortex. (A) 20 ng RNA equivalents were
ampliﬁed as described in Section 2. Primer concentrations were ﬁxed
(see Table 1), except for TRb1 and TRb2 primers, which were varied as
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mize ampliﬁcation conditions. We next ampliﬁed all targets in the same
tube, starting with equimolar primer concentrations (200 nM of each
primer). After adjustments, ﬁnal concentrations of each primer set
ranged from 50 to 800 nM (Table 1).
2.5. Multiplex reaction component optimization
Salt concentrations, dNTP concentration and Taq DNA polymerase
availability aﬀect multiplex performance. Each parameter was tested
and optimized separately. The optimal multiplex PCR mix was found
to be: 50–800 nM of each primer set (see Table 1), dATP, dTTP,
dGTP: 400 lM, dCTP: 25 lM, 2 lCi of [a-32P]dCTP, 1.5 of PCR
buﬀer, and 2.5 units of Taq DNA polymerase per 50 ll of reaction
(thermal proﬁle: 94 C, 5 min; 26 cycles of 94 C, 1 min, 60 C, 1 min,
72 C, 2 min; ﬁnal elongation: 8 min).
2.6. Quantitation
For quantifying and comparing physiological situations, an invari-
ant endogenous standard must be included. We used Ambion’s
QuantumRNATM 18S Internal Standard kit (using 18S/‘‘competimer’’
ratio of 1/9) which was ampliﬁed simultaneously with 5 or 20 ng of
RNA equivalents as described above. PCR products were separated in
a 10% polyacrylamide minigel in 1 Tris–Borate–EDTA buﬀer (2 h/
100 V). Fixed gels were dried before overnight exposition with a
storage Phosphor screen (Molecular Dynamics, Amersham Pharmacia
Biotech) and intensity was measured by PhosphorImager (Molecular
Dynamics), then quantiﬁed with the ImageQuant software (Molecular
Dynamics). Amounts of each speciﬁc product were expressed as a
percent of internal standard.
2.7. Statistical analysis
Means S.E.M. are given for indicated sample numbers (each
sample representing a pool of three animals). Statistical comparisons
between controls and treated groups were done using unpaired Stu-
dent’s t-test. Diﬀerences were considered signiﬁcant at P < 0:05. When
appropriate, ANOVA analysis was also used, giving the same levels of
signiﬁcance.indicated. Optimal conditions were found to be 50 nM of TRb1 and 250
nM of TRb2. (B) Nine targets were simultaneously ampliﬁed with an
internal control (18S) from 5 to 20 ng of RNA equivalents from PVN
or cortex, with [a-32P]dCTP for PhosphorImager semi-quantitation.
Individual gene expression was compared across control and T3-
treated (T3) or PTU-treated (PTU) animals. Note that ampliﬁed
product increases with the amount of RNA used, conﬁrming PCR
linearity.3. Results
We ﬁrst optimized the semi-quantitative multiplex method.
For the primers, annealing temperatures between 52 and 60 C
were tested and the highest usable (60 C) chosen. Individual
primer concentrations required adjustment, as each target is
expressed at diﬀerent levels, a fact that induces variable com-
petition for the ampliﬁcation. Fig. 1A shows an example of
such competition. When no TRb1 primers are present, TRa1
ampliﬁes well, whereas when TRb1 primers are introduced,
TRa1 ampliﬁcation is less eﬃcient. We determined optimal
concentrations for each primer set to achieve equivalent yields
of all PCR products and similar levels of ampliﬁcation as when
the primers were ampliﬁed individually. These conditions werecritical for subsequent semi-quantiﬁcation. We conﬁrmed re-
action linearity using 3 concentrations of RNA equivalents (5,
20 and 100 ng), using 10 cycles more than the number of cycles
used in the ﬁnal condition (26 cycles). We obtained dose-de-
pendent ampliﬁcations (data not shown).
This optimized semi-quantitative multiplex RT-PCRmethod
was used to compare, in two brain areas, the expression of sev-
eral genes (TRH, four TRs isoforms and four co-modulators)
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ﬁcation of targets, 18S rRNA was ampliﬁed as an internal
standard. Target signals showed linear dependence on cDNA
quantity (5 or 20 ng of RNA equivalents) introduced in the re-
action (Fig. 1B). Thus, ampliﬁcation was concentration-
dependent ensuring that changes observed in the ratio of a given
gene PCR product to 18S PCR product truly reﬂected a change
in RNA abundance. The tissue speciﬁcity and physiological
relevance of the system was conﬁrmed by the observation that
the 45% increase in TRH gene expression in the PVN of hypo-
thyroid animals was in the same order of magnitude as previ-
ously reported [1], and thatTRH expressionwas absent from the
cortex of all groups (Fig. 1B). By simplex PCR (data not shown),
we veriﬁed that this gene was not expressed in the cortex,
conﬁrming that the multiplex system was not responsible for
non-ampliﬁcation.
To study eﬀects of hypo- and hyperthyroidism on gene ex-
pression, relative quantiﬁcation was done, starting with two
genes that are neither functional TRs nor co-modulator pro-
tein: TRH and TRa2. Hypothyroidism (6-n-propyl-2-thiouracil
(PTU) treatment) signiﬁcantly increased TRH expression inFig. 2. Tissue speciﬁc regulation of TRH and TRa2 expression by
thyroid status in PVN and cortex: following multiplex PCR, the
amounts of TRH and TRa2 RNA are quantiﬁed and expressed as a
percent of the internal standard. In this and the following ﬁgures,
values are given as means S.E.M., n ¼ 8–14. P < 0:05, P < 0:001,
P < 0:0001 compared to control group. Control (), T3-treated (j),
PTU-treated ( ).the PVN (+44%, P < 0:0001), whereas hyperthyroidism (T3
treatment) decreased to a lesser, but signiﬁcant, extent ()12%,
P < 0:05) the expression of TRH in the same brain region
(Fig. 2A). TRH was not expressed in the cortex (Fig. 1B), as
expected. In hypothyroidism, TRa2 expression was signiﬁcantly
increased in both brain areas, whereas hyperthyroidism had no
eﬀect on TRa2 expression in either region (Fig. 2A and B).
We next quantiﬁed the expression of functional TR isoforms
(TRa1, TRb1 and TRb2) in the PVN (Fig. 3A) and in the cortex
(Fig. 3B). Clear, tissue speciﬁc, diﬀerences in the eﬀects of
thyroid status were seen. Hypothyroidism strongly increased
the relative levels of both TRb1 (+39%, P < 0:001) and TRb2
(+63%, P < 0:0001) mRNAs in the PVN but not in the cortex
(compare Fig. 3A and B), whereas no signiﬁcant eﬀect of hy-
perthyroidism or hypothyroidism versus controls was observed
on TRa1 expression in the PVN. However, ANOVA applied to
the TRa1 data showed the diﬀerences between hypothyroid and
hyperthyroid samples to be signiﬁcant (P < 0:01). In contrast,
hyperthyroidism caused an extremely signiﬁcant decrease of
TRa1 gene expression in the cortex ()36%, P < 0:0001) but not
in the PVN, where the decrease is not signiﬁcant compared toFig. 3. Tissue speciﬁc regulation of TRa1, TRb1 and TRb2 expression
by thyroid status in PVN and cortex: following multiplex PCR, the
amounts of TRa1, TRb1 and TRb2 RNA are quantiﬁed and expressed
as a percent of the internal standard. Control (), T3-treated (j),
PTU-treated ( ).
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on the expression of TRb1 and TRb2 isoforms neither in the
PVN nor in the cortex.
Similarly, clear-cut tissue speciﬁcity was seen when exam-
ining the eﬀects of thyroid status on co-modulator expression
(Fig. 4). In the PVN, hypothyroidism increased the expression
of both co-activators, CREB-Binding Protein (CBP) and Ste-
roid Receptor-Coactivator 1 (SRC1) (+27%, P < 0:001 and
+47%, P < 0:0001, respectively), and of both two co-repressors
examined: Silencing Mediator for Retinoid and Thyroid hor-
mone receptor (SMRT) and Nuclear Receptor Co-Repressor
(NCoR) (+93% and +88%, respectively, P < 0:0001) (Fig. 4A).
In contrast, in the cortex, the eﬀect of hypothyroidism on co-
modulator expression was limited to a slight (+28%), but sig-
niﬁcant (P < 0:05), increase in SMRT levels (Fig. 4B). The
eﬀects of hyperthyroidism were less marked in both the PVN
and the cortex. In the PVN, only CBP levels were signiﬁcantly
repressed by T3 treatment ()26%, P < 0:0001) (Fig. 4A),
whereas in the cortex a small, but signiﬁcant reduction in
SMRT levels ()16%, P < 0:05) was observed (Fig. 4B).Fig. 4. Tissue speciﬁc regulation of the co-modulator CBP, SRC1,
SMRT and NCoR expression by thyroid status in PVN and cortex:
following multiplex PCR, the amounts of CBP, SRC1, SMRT and
NCoR RNA are quantiﬁed and expressed as a percent of the amount
of the internal standard. Control (), T3-treated (j), PTU-treated ( ).4. Discussion
We compared thyroid status eﬀects on the expression of
TRH itself, four TR isoforms (TRa1, TRa2, TRb1 and TRb2) and
four co-modulators potentially involved in TRH transcription
(two co-activators, CBP and SRC1 and two co-repressors,
NCoR and SMRT). Our working hypothesis was that genes
encoding proteins involved in transcriptional control of TRH
might undergo coordinated, tissue-speciﬁc regulation by
physiological signals, in a manner similar to that reported for
coordinated developmental expression of genes involved in the
given pathways [8]. First, we analyzed if these genes showed
co-regulation under physiological variations, i.e., hypo- or
hyperthyroidism. Second, we studied if this regulation was
speciﬁc to the site of regulated TRH transcription, i.e., the
PVN [1,2].
To this end, we set up and optimized a semi-quantitative
multiplex RT-PCR method. This approach was dictated by the
very low quantities of material available (each mouse PVN
weighs <1 mg).
We found ﬁrst signiﬁcant physiological co-regulations of
multiple genes in a restricted brain area and second, that PTU
treatment induces larger regulatory responses than T3 treat-
ment. This latter ﬁnding suggests that the brain is more pro-
tected against hyperthyroidism than hypothyroidism. One of
the eventual explanations is that despite the rapid entry of T3
into the brain [9,10], hyperthyroidism would be actively buf-
fered by inactivating deiodinases, in particular, Type 3 iodo-
thyronine deiodinase (D3), the major T3- and T4-inactivating
enzyme (for review, see [11]) levels of which increase in hy-
perthyroidism throughout the CNS.4.1. Hypothyroidism increases TRb but not TRa1 expression in
the PVN
In the PVN, both TRb mRNA isoforms were signiﬁcantly
increased by hypothyroidism, whereas for TRa1 mRNA, the
regulation was not signiﬁcant compared to the control group.
Of the three main functional isoforms (TRa1, TRb1 and TRb2),
TRa1 is most ubiquitously expressed [12], whilst TRb1 has amore
restricted yet still relatively wide distribution, showing high
expression in the CNS and liver. TRb2 expression is tightly re-
stricted to the CNS, being strongly expressed in the pituitary [13]
and the PVN [14]. Recently, an in vivo study with knock-out
mice lacking the TRb2 isoform [15] showed that the T3-depen-
dent repression of TRH in the PVNwas completely abolished in
TRb2 null-mice, suggesting that this isoform plays a critical role
in the mediation of T3 negative feedback on the hypothalamic–
pituitary–thyroid axis. Moreover, Dupre et al. [5] show that in
new-born TRb= mice, TRH regulation is abolished, and is
rescued by either TRb1 or TRb2 overexpression but not TRa1. The
result reported here, showing speciﬁc regulation of the TRb
isoforms, consolidates the idea that TRb1 and TRb2 are the key
isoforms involved in TRH regulation in the hypothalamus
([5,15–19]).Moreover, it is important to note that the regulation
of TRb mRNA is strictly tissue speciﬁc, and occurs only in the
PVN, the brain region involved in the hypothalamic–pituitary–
thyroid axis regulation, but not in the cortex.
As to TRa1, which according to most reports [5,16,17] is
apparently not involved in the negative regulation of TRH, we
ﬁnd that its mRNA is not signiﬁcantly modiﬁed by hypothy-
roidism compared to control in the PVN, but is strongly
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that this isoform may play a more general role on the control
of the brain homeostasis and brain activity.
4.2. Brain region speciﬁc regulation of nuclear receptor
co-modulators by hypothyroidism
Hypothyroidism increases the expression of all the co-
modulators studied in the PVN. At ﬁrst sight, it seems striking
that co-repressors and co-activators are regulated in a similar
manner, despite the fact that they can have opposite eﬀects on
transcription of many positively regulated genes. However,
here we are dealing with a brain region where TRH gene is
negatively regulated, and the roles and relative contributions
of co-modulators in this regulation have yet to be elucidated.
Moreover, several studies have suggested that co-repressors
and co-activators may reside in the same complex. For in-
stance, Li et al. [20] have shown that NCoR and SMRT interact
with the co-activator ACTR (Activator of Thyroid Receptor)
and that interestingly, this interaction, at least for NCoR, en-
hanced TRb-mediated activation, with the presence of NCoR
raising the local concentration of co-activator at the target gene
promoter. Likewise, NCoR and CBP have been shown to bind
simultaneously to the homeobox heterodimer pbx-hox [21].
Thus, our ﬁndings of a co-regulation of co-activators and
co-repressors are consistent with this hypothesis of their
co-existence and possible interaction within a single-unit.
4.3. Exploitation of semi-quantitative multiplex RT-PCR
To our knowledge, it is the ﬁrst time that semi-quantitative
multiplex RT-PCR has been used for simultaneously following
nine diﬀerent target RNAs. Ideally, this method should be
adapted to real time PCR to achieve better quantiﬁcation.
However, even using the most recent real-time PCR apparatus
available, one cannot actually analyze more than three,
sometimes four, targets (including the internal standard) in the
same tube. Here, we were working on RNA extracted from the
PVN of adult mice. The two PVN from a single brain weigh
<1 mg and so the PVNs from three brains were pooled to
ensure extraction of suﬃcient total RNA (about 5 lg) of good
quality. Thus, we needed to analyze several genes simulta-
neously on limited starting material, which also excluded the
use of cDNA microarrays, which would have required ap-
proximately 400 PVNs per condition tested. What is more,
DNA microarray methodology is rather with insensitive a
twofold diﬀerence between groups being necessary to be con-
sidered relevant. The multiplex approach revealed variations
of at least 30–40%, which is more than relevant for physio-
logical eﬀects, especially as we are dealing with regulatory
proteins.
The observed tissue speciﬁc co-regulation of a set of genes
within the hypothalamus raises the question of the mechanisms
involved. Clearly, one might expect conserved regulatory se-quences such as TREs in the promoter regions of the target
gene concerned. An in silico approach coupled with a func-
tional assay to test putative conserved sequences would be the
ideal method to verify such a hypothesis.
In conclusion, this is the ﬁrst demonstration of brain
region speciﬁc co-regulation by thyroid status of a given
gene set. This co-regulation of genes by thyroid status
within a deﬁned area of the hypothalamus underscores the
physiological requirement for coordinated gene expression
that should facilitate the integrative functions of this brain
region.
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